S&P 500   4,574.79
DOW   35,756.88
QQQ   379.12
S&P 500   4,574.79
DOW   35,756.88
QQQ   379.12
S&P 500   4,574.79
DOW   35,756.88
QQQ   379.12
S&P 500   4,574.79
DOW   35,756.88
QQQ   379.12

Cellect Biotechnology Stock Forecast, Price & News

+0.37 (+2.88 %)
(As of 10/26/2021 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
Volume61,542 shs
Average Volume484,186 shs
Market Capitalization$12.90 million
P/E RatioN/A
Dividend YieldN/A
30 days | 90 days | 365 days | Advanced Chart
Receive APOP News and Ratings via Email

Sign-up to receive the latest news and ratings for Cellect Biotechnology and its competitors with MarketBeat's FREE daily newsletter.

Cellect Biotechnology logo

About Cellect Biotechnology

Cellect Biotechnology Ltd. engages in the provision of regenerative medicine. Its activities include development of regenerative medicine through the development of products facilitating immune stem cell selection. The company also develops innovative technology, which allows the default stem cells by dramatically reducing of complications existing in conventional selection methods. The company was founded by Kasbian Nuriel Chirich, Shai Yarkoni, and Nadir Askenasy on August 4, 1986 and is headquartered in Kfar Saba, Israel.


See More Headlines

Industry, Sector and Symbol

Surgical & medical instruments
Current Symbol
Year Founded

Sales & Book Value

Annual Sales
Book Value
$1.19 per share


Net Income
$-5.62 million




Market Cap
$12.90 million
Next Earnings Date
11/19/2021 (Estimated)
Not Optionable


Overall MarketRank

0.96 out of 5 stars

Medical Sector

1250th out of 1,363 stocks

Surgical & Medical Instruments Industry

118th out of 124 stocks

Analyst Opinion: 0.0Community Rank: 4.8Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Cellect Biotechnology (NASDAQ:APOP) Frequently Asked Questions

What stocks does MarketBeat like better than Cellect Biotechnology?

Wall Street analysts have given Cellect Biotechnology a "N/A" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Cellect Biotechnology wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Cellect Biotechnology?

Cellect Biotechnology saw a drop in short interest in the month of September. As of September 15th, there was short interest totaling 72,000 shares, a drop of 52.8% from the August 31st total of 152,700 shares. Based on an average daily trading volume, of 471,900 shares, the days-to-cover ratio is presently 0.2 days.
View Cellect Biotechnology's Short Interest

When is Cellect Biotechnology's next earnings date?

Cellect Biotechnology is scheduled to release its next quarterly earnings announcement on Friday, November 19th 2021.
View our earnings forecast for Cellect Biotechnology

How were Cellect Biotechnology's earnings last quarter?

Cellect Biotechnology Ltd. (NASDAQ:APOP) released its earnings results on Tuesday, August, 24th. The company reported ($0.86) earnings per share (EPS) for the quarter.
View Cellect Biotechnology's earnings history

How has Cellect Biotechnology's stock been impacted by Coronavirus (COVID-19)?

Cellect Biotechnology's stock was trading at $3.42 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, APOP shares have increased by 286.0% and is now trading at $13.20.
View which stocks have been most impacted by COVID-19

When did Cellect Biotechnology's stock split? How did Cellect Biotechnology's stock split work?

Cellect Biotechnology's stock split before market open on Tuesday, October 26th 2021. The 2-1 split was announced on Tuesday, October 26th 2021. The newly minted shares were issued to shareholders after the market closes on Tuesday, October 26th 2021. An investor that had 100 shares of Cellect Biotechnology stock prior to the split would have 200 shares after the split.

Who are Cellect Biotechnology's key executives?

Cellect Biotechnology's management team includes the following people:
  • Shai Yarkoni, Chief Executive Officer & Director
  • Amos Ofer, Chief Operating Officer
  • Yaron Ben-Oz, Chief Financial Officer

What other stocks do shareholders of Cellect Biotechnology own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Cellect Biotechnology investors own include Elbit Systems (ESLT), Gilead Sciences (GILD), Protalix BioTherapeutics (PLX), Pluristem Therapeutics (PSTI), NVIDIA (NVDA), Teva Pharmaceutical Industries (TEVA), Acasti Pharma (ACST), Allergan (AGN), Novavax (NVAX) and RedHill Biopharma (RDHL).

What is Cellect Biotechnology's stock symbol?

Cellect Biotechnology trades on the NASDAQ under the ticker symbol "APOP."

How do I buy shares of Cellect Biotechnology?

Shares of APOP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Cellect Biotechnology's stock price today?

One share of APOP stock can currently be purchased for approximately $13.20.

How much money does Cellect Biotechnology make?

Cellect Biotechnology has a market capitalization of $12.90 million.

How many employees does Cellect Biotechnology have?

Cellect Biotechnology employs 2,020 workers across the globe.

What is Cellect Biotechnology's official website?

The official website for Cellect Biotechnology is www.cellect.co.

Where are Cellect Biotechnology's headquarters?

Cellect Biotechnology is headquartered at 23 HATA`AS STREET, KFAR SABA L3, 44425.

How can I contact Cellect Biotechnology?

Cellect Biotechnology's mailing address is 23 HATA`AS STREET, KFAR SABA L3, 44425. The company can be reached via phone at (729) 974-1444 or via email at [email protected].

This page was last updated on 10/27/2021 by MarketBeat.com Staff


Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.